Aims and scope Subscription Info for authors Editor-in-chief Editorial Board Contacts
International journal of Immunopathology, allergology, infectology.

Effectiveness of autoserotherapy and glucosaminylmuramildipeptide in bronchial asthma

Sidarenk A.V., Vykhrystsenka L.R.

Vitebsk State Medical University, Vitebsk

Objectives. To analyze the clinical efficacy of autoserotherapy and glucosaminylmuramyldipeptide (lycopid) in patients with bronchial asthma (BA) in clinical practice.
Materials and methods. The study included 58 patients of the Allergy Department of the Vitebsk Regional Clinical Hospital with allergic and mixed (allergic and non-allergic) BA aged 18 to 60 years. 20 patients (group 1) received standard pharmacotherapy (PT) for BA according to the protocol of the Ministry of Health of the Republic of Belarus and a 10-day course of autoserotherapy. 18 patients with clinical manifestations of immunodeficiency (more than 4 moderate exacerbations of BA per year induced by acute respiratory infections) group 2, received a 10-day course of immunostimulating a course of immunostimulating therapy with glucosaminylmuramyldipeptide (Russian Federation, Peptek) and PT. 20 patients (group 3) receiving only PT served as a positive control. Multipurpose monitoring of the condition was carried out in all patients, the level of control of asthma symptoms (AST test), the need for β2-agonists, the frequency of exacerbations during the year, and the effectiveness of therapy were assessed.
Results. After 12 months of treatment in groups 1 and 2, the need for short-acting β2-agonists decreased (p<0.001); in group 1, BA control increased to complete (p<0.001). The number of exacerbations in group 1 decreased to their complete absence (p<0.001) and significantly in group 2 (p<0.001). 60% (12/20) of patients in group 1 considered the effect of treatment excellent, there were no exacerbations of BA for 2 years. In patients of group 2 during the year.
Conclusions. Autoserotherapy and lycopid immunotherapy are effective treatments: they show a reduction in the need for short-acting β2-agonists in both groups, 100% reduction in exacerbations in group 1 and 50% in group 2.


Bronchial asthma, autoserotherapy, glucosaminylmuramyl-dipeptide, immunotherapy.

Fulltext in PDF

Open file
Size: 172 KB




Sidarenk A.V., Vykhrystsenka L.R. Immunopathology, allergology, infectology 2022; 4:30-35. DOI: 10.14427/jipai.2022.4.30